anti-HER3 antibody drug conjugate (Elevation Oncology)

N/A

Report date: 2025/06/11 10:42:01

Base Information

Drug Nameanti-HER3 antibody drug conjugate (Elevation Oncology)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 modulators

TargetsReceptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesElevation Oncology Inc

China Registration ClassN/A

Develop Information

Active CompaniesElevation Oncology Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A